Intelligent Investor

Novogen Limited

By · 2 Jul 1999
By ·
2 Jul 1999
Upsell Banner
The market has been kind to this biotechnology company. On Friday 25 June it announced that it was able to raise more capital in an institutional placement of 8.8 million shares at $2.77. This adds to the recent good news on 15 June regarding the NV-06 drug, which will have application in the treatment of prostate cancer. As company recognition increases, driven by the market penetration of its Promensil drug, we expect interest to remain high and maintain our positive view of issue 14. SPECULATIVE BUY for the brave hearted.
IMPORTANT: Intelligent Investor is published by InvestSMART Financial Services Pty Limited AFSL 226435 (Licensee). Information is general financial product advice. You should consider your own personal objectives, financial situation and needs before making any investment decision and review the Product Disclosure Statement. InvestSMART Funds Management Limited (RE) is the responsible entity of various managed investment schemes and is a related party of the Licensee. The RE may own, buy or sell the shares suggested in this article simultaneous with, or following the release of this article. Any such transaction could affect the price of the share. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.
Share this article and show your support

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here